Recombinant soluble CD32 suppresses disease progression in experimental epidermolysis bullosa acquisita

J Invest Dermatol. 2015 Mar;135(3):916-919. doi: 10.1038/jid.2014.451. Epub 2014 Oct 20.

Authors

Hiroaki Iwata¹, Elena Pipi¹, Nicole Möckel¹, Peter Sondermann², Artem Vorobyev³, Nina van Beek¹, Detlef Zillikens³, Ralf J Ludwig⁴

Affiliations

¹ Department of Dermatology, University of Lübeck, Lübeck, Germany.
² SuppreMol GmbH, Munich, Germany.
³ Department of Dermatology, University of Lübeck, Lübeck, Germany; Institute of Experimental Dermatology, University of Lübeck, Lübeck, Germany.
⁴ Department of Dermatology, University of Lübeck, Lübeck, Germany; Institute of Experimental Dermatology, University of Lübeck, Lübeck, Germany. Electronic address: Ralf.Ludwig@uksh.de.

PMID: 25330298
DOI: 10.1038/jid.2014.451

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Animals
Antigen-Antibody Complex / metabolism
Disease Models, Animal
Disease Progression*
Epidermolysis Bullosa Acquisita / metabolism
Epidermolysis Bullosa Acquisita / prevention & control*
Humans
Mice
Reactive Oxygen Species / metabolism
Receptors, IgG / therapeutic use*
Recombinant Proteins / therapeutic use
Treatment Outcome

Substances

Antigen-Antibody Complex
Reactive Oxygen Species
Receptors, IgG
Recombinant Proteins